History
September 2017: Phase I/II investigator-initiated clinical trial of amniotic mesenchymal stem cells for Crohn's disease begins
November 2017: Phase I/II investigator-initiated clinical trial of amniotic mesenchymal stem cells for acute GVHD begins
Established in February 2018 with the aim of commercializing amniotic mesenchymal stem cells.
April 2018: Certified as a venture company from Hyogo College of Medicine
December 2018: Third-party allotment of new shares with Hyogo College of Medicine as an investor
Company Profile
Company name: Seetex Co., Ltd.
CTEX Co., Ltd.
Established February 28, 2018
Capital: 2 million yen
Representative : Kenichi Yamahara
Business descriptionRegenerative medicine products, medical equipment manufacturing, academic research, professional and technical services
Toshihiro Souma, Executive Director
Director Hideki Takeda
Auditor Seiichi Okabe
Contact Us
TEL:0798-45-6413
FAX:0798-45-6119
Email: info[at]c-tex.jp
〒663-8501
1-1 Mukogawacho, Nishinomiya City, Hyogo Prefecture
Education and Research Building, 8th floor